Key result
Inhibition of i-tRF-Asp ameliorates hypoxia-induced pulmonary vascular remodeling by suppressing PASMC proliferation.
Answers are grounded in this paper and cite their sources.
Inhibition of i-tRF-Asp ameliorates hypoxia-induced pulmonary vascular remodeling in preclinical models, identifying a novel epigenetic mechanism and potential therapeutic target for pulmonary hypertension.
BACKGROUND: Pulmonary hypertension (PH) is a fatal disease characterized by pulmonary vascular remodeling, primarily driven by excessive proliferation of pulmonary arterial smooth muscle cells (PASMCs). Although noncoding RNAs, such as circular RNAs, have been implicated in PH, the role of tRNA-derived small RNA remains poorly understood. Among them, i-tRF (internal tRNA-derived fragment)-Asp represents a novel tRNA-derived small RNA whose function in hypoxic PH is unknown. This study aims to investigate whether i-tRF-Asp contributes to PASMC proliferation and vascular remodeling in hypoxic PH. METHODS: To elucidate the functional role of i-tRF-Asp, loss-of-function experiments were conducted in vitro using hypoxic mouse PASMCs, alongside in vivo studies using both SuHx (Sugen5416+hypoxia) induced PH models in both adult male C57BL/6 mice and Sprague-Dawley rats. These models employed antisense oligonucleotide inhibitors and adeno-associated virus-mediated silencing. The underlying mechanisms were further explored via RNA immunoprecipitation, liquid-liquid phase separation assays, cell proliferation assessment, Western blot, alternative splicing profiling, and molecular dynamics simulation. RESULTS: Inhibition of i-tRF-Asp ameliorated hypoxia-induced pulmonary vascular remodeling, primarily through suppressing excessive proliferation of mouse PASMCs. Further analysis indicated that i-tRF-Asp facilitates liquid-liquid phase separation of hnRNPU (heterogeneous nuclear ribonucleoprotein U). This process mediates selective recruitment of Tcf7l2 (transcription factor 7-like 2) pre-mRNA and promotes alternative splicing, resulting in a pro-proliferative Tcf7l2 transcript variant that drives mouse PASMC proliferation. Furthermore, we have identified that the endonuclease ERN1 (endoribonuclease IRE1) can upregulate the expression of i-tRF-Asp. CONCLUSIONS: The endoribonuclease ERN1 upregulates the expression of i-tRF-Asp, which in turn facilitates mouse PASMC proliferation and pulmonary vascular remodeling. This process is driven by hnRNPU liquid-liquid phase separation-dependent alternative splicing of the long Tcf7l2 transcript isoform.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2026) studied Hypoxic pulmonary hypertension. Inhibition of i-tRF-Asp vs. Control was evaluated on Hypoxia-induced pulmonary vascular remodeling and PASMC proliferation. Inhibition of i-tRF-Asp ameliorated hypoxia-induced pulmonary vascular remodeling by suppressing excessive proliferation of mouse PASMCs via hnRNPU phase separation and Tcf7l2 alternative splicing.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: